Navigation Links
MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
Date:9/11/2007

preferred shares into 158,342 common shares in respect of a milestone achieved in the MX-2401 program in April 2007. As of August 31, 2007 the 4,000,000 Series E preferred shares representing potential milestone payments of US$4,000,000 can be redeemed for the aggregate sum of US$1 following the expiry of the milestone obligations associated with these preferred shares.

----------------------------------------------------------------------- --

Conference Call

Investors, analysts and the media are invited to participate in a conference call Tuesday September 11, 2007 at 11:00 a.m. ET (8:00 a.m. PT) to discuss this announcement. To participate in the conference call, please dial 416-644-3415 or 1-800-732-9303. The call will be available for replay until September 25, 2007 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21244947 followed by the number sign. The live and archived web cast can be accessed through the company's website at http://www.migenix.com for the next 90 days.

-------------------------------------------------------------------------

Selected Financial Highlights

BALANCE SHEETS July 31, April 30,

Unaudited - In Thousands of Canadian dollars 2007 2007

-------------------------------------------------------------------------

Assets

Cash and cash equivalents $7,376 $2,945

Short-term investments 5,437 12,365

Other current assets 1,318 1,245

-------------------------------------------------------------------------

Total current assets $14,131 $16,555

Long-term investments 1 1

Equipment 928
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 Immunovaccine ... made aware of a fraudulent press release disseminated this ... to be from Immunovaccine. This press release states that ... Science, Inc. The press release did not originate ... information contained within the press release. Please note ...
(Date:2/27/2015)... SUMMERLAND, British Columbia , Feb. 27, ... XON ), a leader in synthetic biology, today announced ... Specialty Fruits (OSF), the pioneering agricultural company behind ... first non-browning apple. Through the acquisition, Intrexon expands its ... more appetizing and convenient for consumers while providing economic ...
(Date:2/27/2015)... 27, 2015  Pharmacyclics, Inc. (NASDAQ: ... for its newly developed Bruton,s tyrosine kinase (BTK) ... completed. The results of these preclinical evaluations have ... Administration. The feedback received from the Agency is ... study. Additional preclinical work is required to begin ...
(Date:2/27/2015)... , Feb. 27, 2015 A ... the NCATS rare-diseases portfolio " in Science ... new financing technique to reduce the risk associated ... and potentially unlock new levels of funding for ... product of a unique collaboration between scientists at ...
Breaking Biology Technology:Immunovaccine Disclaims Hoax Press Release 2Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... with Teleflex ... -- ... Pa., Aug. 24 Arrow International,Inc. (Nasdaq: ARRO ) today announced ... Arrow shareholders definitive proxy,materials in connection with the Company,s 2007 Annual Meeting ...
... Mass., ROSEMONT, Ill. and EDMONTON, Alberta, Aug. ... Haemonetics Software Solutions, Inc. to provide innovative,information ... collection,industries. Haemonetics Software Solutions is the ... 5D Information Management, Inc. ("5D") and,Information Data ...
... 24 AGA Medical Corporation ("AGA"),announced today that ... and European CE Mark approvals for the AMPLATZER ... Vascular Plug II expands the AGA family of ... and blood vessel,malformations in the peripheral vasculature. The ...
Cached Biology Technology:Arrow International Files and Mails Definitive Proxy Materials 2Arrow International Files and Mails Definitive Proxy Materials 3Arrow International Files and Mails Definitive Proxy Materials 4Haemonetics Announces New Subsidiary, Haemonetics Software Solutions 2AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II 2
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... DIEGO , Jan. 26, 2015   Epic Sciences ... of cancer, today announced that Murali Prahalad , Ph.D., ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which ... Mountain View, Calif. on January 26-28, 2015. ... "CTCs Come of Age as Biomarkers." Last year, Epic Sciences ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... reports a high prevalence of vitamin D insufficiency and ... vitamin D levels was not observed in patients in ... Arthritis Care & Research , a journal of ... association between disease activity and vitamin D level. ...
... capacity to buffer against climate change? As one ... takes up roughly one-third of all human carbon emissions, ... But whether the ocean can continue mopping up ... in the air. Previous studies on the topic have ...
... researchers have derived inspiration from the photosynthetic apparatus in ... control and direct the energy absorbed from light. ... Nature Nanotechnology, which will be released on ... led by Professors Shana Kelley and Ted Sargent, report ...
Cached Biology News:Vitamin D insufficiency prevalent among psoriatic arthritis suffers 2Climate change reducing ocean's carbon dioxide uptake 2Climate change reducing ocean's carbon dioxide uptake 3U of T researchers build an antenna for light 2
quantitation of phosphatase activity, evaluation of hits and leads from HTS...
... Quality ISO 9001:2000 Certified USDA Research ... Validated, SOP's Training AALAS Certified ... All Procedures GLP Documentation Upon Request ... shopping point for all your custom immunology ...
Request Info...
Request Info...
Biology Products: